Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
122 hedge funds and large institutions have $75.9M invested in Esperion Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 22 closing their positions.
398% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $335K
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 124 → 122 (-2)
6.31% less ownership
Funds ownership: 78.54% → 72.23% (-6.3%)
27% less capital invested
Capital invested by funds: $104M → $75.9M (-$27.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$6.84M |
| 2 |
Millennium Management
New York
|
+$3.54M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.66M |
| 4 |
JP Morgan Chase
New York
|
+$2.37M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$12.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.72M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.33M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$1.25M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$885K |
ESPR Hedge Fund Activity: Q3 2023 in Review
122 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2023, worth a combined $75.9M — down 27% from $104M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ESPR and 21 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 36 added.
The largest buyer was Two Seas Capital, adding an estimated $6.84M. The largest seller was Armistice Capital, exiting entirely with an estimated $12.8M sold.
- 122 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2023, down from 124 in Q2 2023.
- Funds reported $75.9M of Esperion Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
- 21 funds opened new Esperion Therapeutics positions in Q3 2023 and 22 closed out, a net change of -1 holder.
- The largest Esperion Therapeutics buyer in Q3 2023 was Two Seas Capital, an estimated $6.84M added.
- The largest Esperion Therapeutics seller in Q3 2023 was Armistice Capital, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2023.